Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05517109
Other study ID # IVT-160
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 12, 2022
Est. completion date January 10, 2025

Study information

Verified date March 2024
Source Northern State Medical University
Contact Alexey Avidzba
Phone 9115905137
Email avidzba_a@rambler.ru
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators are suggtesting that lower goals of systolic blood pressure after intravenous thrombolysis may reduce the risk of hemorrhagic complications and improve functional outcomes after acute ischemic stroke.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date January 10, 2025
Est. primary completion date January 10, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion ?riteria: - ischemic stroke diagnosis - performed intravenous thrombolysis (including "wake up stroke") - systolic blood pressure >140 mmHg - informed consent or council of physician agreement Exclusion criteria: - absence of informed consent or council of physician agreement - pregnancy - patients participainting in other clinical trial in the last 90 days - any absolute contraindications to intravenous thrombolysis ?ompletion criteria: - failure to achieve hemodynamic goal for 20 minutes before the start of intravenous thrombolysis - failure to achieve hemodynamic goal for 60 minutes in first 24 hours after intravenous thrombolysis - relative arterial hypotension (SBP <100 mmHg for 60 minutes in first 24 hours after intravenous thrombolysis) - unfavorable effect development (e.g. seizures, angioedema) - informed consent is retracted

Study Design


Intervention

Other:
Hemodynamic goal including lower goal of systolic blood pressure
Different hemodynamic goals in different study arms

Locations

Country Name City State
Russian Federation City Hospital # 1 n.a. E.E. Volosevich Arkhangelsk

Sponsors (1)

Lead Sponsor Collaborator
Northern State Medical University

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Modified Rankin Scale score Fucntional outcome (Modified Rankin Scale) will be assesed by telephone interview. Score from 0 to 6. Higher scores mean a worse outcome. 90 day after intravenous thrombolysis
Primary Mortality rate At 90 day after intravenous thrombolysis
Primary Rate of symptomatic intracranial hemorrhage Symptomatic intracranial hemorrhage (sICH) according to SITS-MOST study description of sICH 24 hours after intravenous thrombolysis
Primary Rate of symptomatic intracranial hemorrhage Symptomatic intracranial hemorrhage (sICH) according to SITS-MOST study description of sICH 7 days after intravenous thrombolysis
Secondary Change in National Institutes of Health Stroke Scale (NIHSS) Score form 0 to 42. Higher score indicates worse outcome at 28 day after intravenous thrombolysis
Secondary Rate of all Intracranial hemorrhage Intracranial hemorrhage will be classified according to Heidelberg bleeding classification 24 hours after intravenous thrombolysis
Secondary Rate of all Intracranial hemorrhage Intracranial hemorrhage will be classified according to Heidelberg bleeding classification 7 days after intravenous thrombolysis
Secondary Lengths of stay in ICU at 90 day after intravenous thrombolysis
Secondary Lengths of stay in hospital at 90 day after intravenous thrombolysis
Secondary Rate of acute kidney injury Acute kidney injury will be assesed according to RIFLE Classification 28 day after intravenous thrombolysis or at discharge
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT06437431 - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy Phase 2/Phase 3
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3